logo
NasdaqCM:VERU logo

Veru Community

NasdaqCM:VERU Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

VERU logo
Veru
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts

Enobosarm Phase III And Sabizabulin Tests Will Yield Mixed Prospects

Key Takeaways Successful clinical trials indicate potential for regulatory approval and commercialization, enhancing future revenue and earnings. Strategic focus on drug development and novel formulations could improve operational efficiency and uncover new market opportunities.
View narrative
US$3.25
FV
84.6% undervalued intrinsic discount
-16.04%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
7 days ago author updated this narrative